Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • US Politics
    US Politics
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

Article Tools/Herramientas de artículos

+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña




Globe NewsWire News Distribution Service

Press Release: Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Details
Category: Globe NewsWire News Distribution Service

Media Release COPENHAGEN, Denmark; June 15, 2025 Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who…


Posted: 2025-06-15 09:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

cell | press | release | genmab


Related Bing News Search Results

Press Release: Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - Newscast

Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL

Mon, 16 Jun 2025 02:34:08 GMT The combo therapy demonstrated an ORR of 87%, with a complete response rate of 65% and a partial response rate of 23%.

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Wed, 01 Nov 2023 17:00:00 GMT COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody ®-CD3xCD20), a T-cell engaging bispecific antibody administered ...

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Fri, 21 Jul 2023 02:30:00 GMT The most common treatment-emergent adverse event was cytokine release syndrome ... are classified as B-cell malignancies. ii Epcoritamab is being co-developed by Genmab and AbbVie as part of ...

Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of ...

Mon, 21 Nov 2022 05:35:00 GMT Genmab A/S (Nasdaq: GMAB)today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody ...

Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse ...

Fri, 28 Oct 2022 05:47:00 GMT Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application ...
Blow Us A Whistle




Related Product Search/Búsqueda de productos relacionados